Isomorphic Labs explores a $40B valuation

Isomorphic Labs is in early funding talks at a valuation of at least $40 billion, according to Bloomberg’s October 8 report citing people familiar with the discussions. The financing has not closed, terms could change, and the company did not respond to Bloomberg’s request for comment. The Alphabet-linked drug-discovery startup’s prospective valuation therefore remains a reported negotiating figure, not money raised or evidence of clinical success. As in our analysis of Enveda’s clinical capital gate, operators should separate financing capacity from the evidence needed to advance a drug program.